GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH - School of Pharmacy · 2020-02-20 · School of Pharmacy, ... technologies, and (3) translate and disseminate the results of research

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCHFELLOWSHIP PROGRAMUNIV OF WASHINGTON2017-2019

GHEOR Fellowship Program 2017-2019

PRODUCT VALUE PROPOSITION…outcomes research strategy based on product value, stakeholder needs & insights

VALUE COMMUNICATION …about evidence informing the value proposition to stakeholders

…informs health care decision making

EVIDENCE GENERATION AND TOOL DEVELOPMENT…through clinical and health economics & outcomes research (HEOR) data

Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new

industry model - Growth Pharma. Our company is focused on developing, manufacturing and commercializing branded

pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands

and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology,

women’s health, urology, and anti-infective therapeutic categories. We are an industry leader in research and development,

with one of the broadest innovative development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline

programs in development. With commercial operations in approximately 100 countries, our company is committed to working

with physicians, healthcare providers and patients to deliver innovative and meaningful treatments to help people around the

world live longer, healthier lives. Learn more at www.Allergan.com.

ABOUT OUR COMPANY

OUR WORLD-CLASS MANUFACTURING AND R&D NETWORK

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR) MISSION


1

2

3

USAFall River, MA

Cincinnati, OH

Northern, CA (Biologics)

Irvine, CA (Biologics)

Waco, TX

Jersey City, NJ

Rockaway, NJ

Bridgewater, NJ

Irvine, CA

COSTA RICAHeredia, San Jose

BRAZILGuarulhos

IRELANDWestport

Clonshaugh, Dublin

Westport

BELGIUMLiege

GERMANYWeiterstadt

FRANCEPringy

Pringy

MANUFACTURING

CHINABeijing

Shanghai

JAPANTokyo

UKLiverpool

Marlow

R&D

SINGAPORESingapore

1

The University of Washington is a world-class leader in health sciences education and has been consistently listed in

US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly

noted for its strong research programs and since 1974 has received more federal funds for research and training

than any other public university in the United States. It fosters a highly collegial atmosphere between departments

and academic units, creating a particularly attractive environment for such partnerships between the public and

private sectors.

The Pharmaceutical Outcomes Research and Policy Program (PORPP) is housed within the University of Washington

School of Pharmacy, which boasts nearly 120 years of academic and research success. Faculty in the program (1)

provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2)

conduct rigorous scientific research in the pharmacoeconomics and outcomes of pharmaceuticals and other health

technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with

the goal of improving patient care.

PORPP faculty participating in the fellowship have been chosen both for their dedication to teaching and their

excellence in research. Each is trained either as a health economist or health services researcher and all have an

extensive history of effective pharmacoeconomic and pharmacoepidemiologic research.

ABOUT OUR SCHOOL

GHEOR Fellowship Program 2017-2019 2

The University of Washington is a world-class leader in health sciences education and has been consistently listed in

US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly

noted for its strong research programs and since 1974 has received more federal funds for research and training

than any other public university in the United States. It fosters a highly collegial atmosphere between departments

and academic units, creating a particularly attractive environment for such partnerships between the public and

private sectors.

The Pharmaceutical Outcomes Research and Policy Program (PORPP) is housed within the University of Washington

School of Pharmacy, which boasts nearly 120 years of academic and research success. Faculty in the program (1)

provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2)

conduct rigorous scientific research in the pharmacoeconomics and outcomes of pharmaceuticals and other health

technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with

the goal of improving patient care.

PORPP faculty participating in the fellowship have been chosen both for their dedication to teaching and their

excellence in research. Each is trained either as a health economist or health services researcher and all have an

extensive history of effective pharmacoeconomic and pharmacoepidemiologic research.

ABOUT OUR SCHOOL

GHEOR Fellowship Program 2017-2019 2


UNIVERSITY OF WASHINGTON

Beth Devine, PharmD, MBA, PhD, FASHP

Associate Professor

Pharmaceutical Outcomes Research & Policy Program

1959 NE Pacifi c Avenue, H-375D

Box 357630

Seattle, WA 98195-7630

E-Mail: [email protected]

THE FELLOWSHIP PROGRAM Allergan and the University of Washington are pleased to off er two, 2-year GHEOR Fellowship positions for the academic year

2017-2019. Fellows will spend their fi rst year at the University of Washington (Seattle, WA), and the second year at Allergan

(Irvine, CA). The objective of the fi rst year is to educate fellows on the principles and methods used in health economics

and outcomes research. During the second year, fellows are provided with opportunities to gain practical knowledge and

experience with the use of clinical, economic, and humanistic data by supporting the development and commercialization of

pharmaceutical products. This will be accomplished by participating in work activities undertaken by the GHEOR team.

Compensation includes a competitive stipend, basic medical insurance, and holiday/vacation time. A Master’s (MS)

Degree is awarded upon completion of all course requirements and thesis project.

ALLERGAN PLC

Patrick Gillard, PharmD, MS

Director, GHEOR

2525 Dupont Drive

Irvine, CA 92612


Phone: (714) 246-2354

FELLOWSHIP DIRECTORS

ABOUT OUR FELLOWSHIPThe Allergan/University of Washington GHEOR Fellowship is a two-year program

that provides training and hands-on experience in a broad-range of health

economics and outcomes research topics. The program is structured to allow

fellows to gain profi ciency in health outcomes strategy and research as conducted

in both academic and pharmaceutical industry settings.

3


FIRST YEAR OBJECTIVESThe objective of the fi rst year is to provide the fellow with the research tools necessary for pharmacoeconomic and

policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy,

and taught methods of economic assessment, health services research, epidemiology, clinical research design, and

biostatistical analyses.

The fellow will be assigned a MS thesis project which is selected based on input from both Allergan as well as the

University of Washington mentors. Fellows are highly encouraged to complete their MS project during their fi rst year.

Additionally, fellows will also engage in ongoing projects with Allergan throughout their fi rst year, applying skills from

previous pharmacy training as well as integrating new techniques developed from University of Washington courses.

Applying learning to solve real-world problems is a constant focus of the fellowship.

The fellow’s actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine,

but will consist of courses in biostatistics, epidemiology, pharmacoeconomics and outcomes research, and health and

pharmaceutical policy.

AFTER COMPLETION OF THE FIRST-YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF:• General principles of economics and in particular how economics infl uences the use, cost, and availability of

pharmaceuticals.

• The complex structure of drug policy and how it determines relationships between consumers, health care providers,

insurers, payers, and government agencies.

• The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs),

economic modeling, retrospective database studies, and observational studies.

• Formulary development, maintenance and evaluation in institutional, managed care, and state-level

government programs.

1ST YEAR

FELLOWSHIP STRUCTURE

4


SECOND YEAR OBJECTIVESThe second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program

is designed to allow the fellow to learn about the role of pharmacoeconomics and outcomes research in the drug

development and commercialization process within the industry setting. The research may be on an existing or

experimental product, for a disease state that is of interest to Allergan.

In addition to completing individual research project(s), fellows will participate in ongoing pharmacoeconomic

evaluations, outcomes research, and other projects in collaboration with the GHEOR team. These experiences will

provide the fellow with opportunities to interact with team members in other

departments at Allergan to learn how economic analyses and outcomes

research are used throughout the pharmaceutical industry. Fellows will

see fi rsthand how outcomes research is utilized to demonstrate the

place of Allergan products in treatment pathways and its value.

2ND YEAR

5


UNIVERSITY OF WASHINGTON PROGRAM FACULTY

• Anirban Basu, PhD Professor and Stergachis Family Endowed

Director of PORPP

• Denise Boudreau, PhD Affi liate Associate Professor

• Beth Devine, PharmD, MBA, PhD, FASHP

Associate Professor, Director of Graduate

Programs

• Josh Carlson, MPH, PhD Associate Professor

• Louis P. Garrison, Jr., PhD Professor Emeritus

• Ryan Hansen, PhD, PharmD Assistant Professor

• Thomas K. Hazlet, PharmD, Dr. PH Associate Professor

• Scott D. Ramsey, MD, PhD Professor

• Sean D. Sullivan, PhD Professor and Dean of

School of Pharmacy

• David L. Veenstra, PharmD, PhD Professor and Associate Director of PORPP

Hema Viswanathan, BPharm, PhDDirector, GHEOR

Jonathan W. Kowalski, PharmD, MSVice President, US HEOR

Sepideh Varon, PhDSenior Director, GHEOR

Katelyn Keyloun, PharmD, MSPrincipal Research Associate, GHEOR

Vanessa Shih, PharmD, MSPrincipal Research Associate, GHEOR

Patrick Gillard, PharmD, MSDirector, GHEOR

Joanna Campbell, PhDDirector, GHEOR

ALLERGAN FELLOWSHIP MENTORS

Vaishali Patel, PharmD, MSSenior Director, GHEOR

• Joseph Babigumira Assistant Professor

• Aasthaa Bansal Research Assistant Professor

• Caroline Bennette Acting Assistant Professor

• Andy Stergachis Professor and Associate Dean for Research,

Graduate Programs and New Initiatives

6


SHEILA SHAPOURI, PHARMDSheila joins the UW/Allergan fellowship after receiving her PharmD from the University of Washington in 2016.

Prior to pharmacy school, she worked as a research associate at the Allen Institute for Brain Science generating

publicly available neuroscience and genetics resources now used by researchers worldwide. Although she has

left the lab, her interest in improving health outcomes at a patient population level through targeted research

continues. During pharmacy school, Sheila completed clinical clerkships at the Food and Drug Administration

(FDA), PATH, and the Centers for Disease Control and Prevention (CDC). There she engaged in the application

of surveillance and outcomes data to guide healthcare decisions and policy at a national and global level.

Sheila participated in the AMCP P&T Competition and her team placed as semi-fi nalists nationally.

Sheila is looking forward to the opportunity to work with the PORPP faculty and Allergan team while gaining

the advanced training necessary to become an eff ective health economics and outcomes researcher. For her

thesis project, she will be building a predictive model for 30-day hospital readmissions or ER re-visits among

patients with acute bacterial skin and skin structure infections (ABSSSI).

MICHAEL SERBIN, PHARMDMichael received his PharmD degree from the University of Washington School of Pharmacy (UWSOP) in 2016

and a BS in biomedical engineering from the University of Southern California in 2011. At UWSOP he worked as

a research assistant and was recently published as a fi rst author in the Journal of Managed Care and Specialty

Pharmacy. Michael has interests in P&T decision-making, formulary development, and the application of

economic modeling. He focused his 4th year PharmD clerkships on formulary development and wrote P&T

submissions at Premera Blue Cross, UW Medical Center, and Providence Health. Michael competed in the

AMCP P&T competition where his team placed as semifi nalists nationally.

This year Michael is excited to start working with PORPP faculty and the GHEOR team at Allergan to improve

his research and economic modeling abilities. For his thesis project, Michael will use the Medical Expenditure

Panel Survey database to assess the societal burden of non-drop (surgery and other procedures) treatment of

glaucoma in patients unsuitable for drop therapy.

1ST YEAR FELLOWS

CURRENT FELLOWS

7


SARAH BARADARAN, PHARMD, MSSarah received her doctorate of pharmacy from the University of Washington (UW) School of Pharmacy in 2015.

During the first year of her fellowship, she was involved in a pharmacogenomic evidence project with her

colleagues at UW, under mentorship from Professor Beth Devine. She also completed her thesis project entitled

"The identification and characterization of acute kidney injury (AKI) associated with systemic polymyxins in the

management of severe gram-negative infections."

During her second year of the fellowship, Sarah has worked in the infectious disease therapeutic area. She is

performing additional analyses to estimate the association between healthcare utilization, cost and acute kidney injury.

She will also begin supporting a project that will be an expansion of her thesis utilizing electronic health records. Sarah

is excited to apply her clinical and research skills on various projects throughout the second year of the fellowship.

ABSTRACTS FROM FELLOWSHIP:

1. Baradaran S, Keyloun K, Chin L, Pham J, Canestaro WJ, Devine B. Clinical evidence supporting

pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels: An update.

ISPOR 21st Annual International Meeting. Washington DC. May 2016 (Poster)

MANUSCRIPTS FROM FELLOWSHIP:

1. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in

FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. September 2016 (under review for

AMIA Joint Summits Meeting 2017)

AMY TUNG, PHARMD, MSAmy received her PharmD degree from the University of Washington (UW) in 2015. During the first year of her

fellowship, she completed her thesis titled “Characterizing Healthcare Utilization, Direct Costs, and Comorbidities

Associated with Interstitial Cystitis: A Retrospective Claims Analysis” under the mentorship of Professor Beth Devine.

During the second year of the fellowship, Amy has worked in the urology therapeutic area. After submitting her

thesis as a manuscript to the Journal of Managed Care Pharmacy, she has been analyzing data from a prospective

burden of illness study on nocturia to understand the association between frequency of nocturia episodes and

quality of life. In tandem, she is conducting a claims analysis to estimate the opioid burden in the interstitial cystitis

population as well as working with cross-functional departments to solicit feedback from global Health Technology

Assessment (HTA) experts on Allergan’s evidence synthesis and strategy plans for LiRIS®. Amy is excited to apply her

training in health economics and outcomes research in the industry setting during the second year of the fellowship.

ABSTRACTS FROM FELLOWSHIP:

1. Tung A, Hepp Z, Devine B. The Economic Burden of Interstitial Cystitis in the United States: A Literature

Review. UW Corporate Advisory Board Meeting. Seattle, WA. September 2015 (Poster)

2. Tung A, Hepp Z, Bansal A, Devine B. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities

Associated with Interstitial Cystitis: A Retrospective Claims Analysis. ISPOR 21st Annual International

Meeting. Washington DC. May 2016 (Poster)

3. Luber K, Kawahara S, Wang D, Tung A, Burk C. The Quality of Life Among Women with Nocturia. American

Urogynecologic Society 37th Annual Scientific Meeting. Denver, CO. September 2016 (Poster)

MANUSCRIPTS FROM FELLOWSHIP:

1. Tung A, Hepp Z, Bansal A, Devine B. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities

Associated with Interstitial Cystitis: A Retrospective Claims Analysis. ISPOR 21st Annual International

Meeting. Washington DC. August 2016 (under review at JMCP)

2ND YEAR FELLOWS

8


Health Economist

Genentech, San Francisco, CA

MANUSCRIPTS FROM FELLOWSHIP1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.Assessing patterns of use of cardio-protective polypill component

medicines in Australian women. Drugs Aging (2013)30:193-203

2. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among

Commercially Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic surgery, lasers & imaging retina.

2015 Jul-Aug;46(7):744-51

3. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially

Insured Working Age Population (2013). (In Progress)

Principal Research Associate, Global Health Economics and Outcomes Research

Allergan plc, Irvine, CA

MANUSCRIPTS FROM FELLOWSHIP1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and

Informal Caregiving Requirements in Older Americans. (In Progress)

Pharmacy Quality, Utilization, and Clinical Programs Coordinator Group Health

Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP 1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by

Disease Severity: A Retrospective Claims Database Analysis. (In Progress)

Principal Research Associate, Global Health Economics and Outcomes Research


MANUSCRIPTS FROM FELLOWSHIP 1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant

Therapeutic Class: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).

(Under review at CNS Drugs)

2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarcyzy-Hornoch P, Devine EB. Characterizing pharmacogenomic-

guided medication use with a clinical data repository. (Under review at Clinical Pharmacology & Therapeutics)

3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. September 2016 (under review for AMIA Joint Summits Meeting 2017)

PAST FELLOWSKATELYN

KEYLOUNPharmD, MS

2014-2016

VANESSA SHIH

PharmD, MS2014-2016

TRACY YEPPharmD, MS

2013-2015

CHRIS WALLICK

PharmD, MS2012-2014

9


Associate Director

Abbvie, Chicago, IL

MANUSCRIPTS FROM FELLOWSHIP1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among

patients with chronic migraine. Cephalalgia. 2015 May;35(6):478-88.

2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in

improving medication safety in ambulatory care. Value Health. 2014 Jun;17(4):340-9

Research Scientist

Evidera, Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive

Bladder with Urinary Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. BMC

Urology, 2009; 9(18)

Assistant Professor, UCSD Skaggs School of Pharmacy

San Diego, CA

MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder

with Urinary Urge Incontinence Refractory Oral Antimuscarinics. BMC Urology, 2009 Nov;20;9(18).

2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for

Antimuscarinic Refractory Patients with Overactive Bladder. Urology, 2010 Oct;76(4):835-40.

3. Sand P, Rovner E, Dmochoswki R, Watanabe JH, Oefelein MG. Once-daily Trospium Chloride 60 mg Extended Release is

Safe and Effective in Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. Drugs

Aging, 2011 Feb;1;28(2):151-60

4. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr

Med Res Opin, 2011 May, 27(5):1041-8.

Director, Global Health Economics and Outcomes Research


MANUSCRIPTS FROM FELLOWSHIP1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease- Specific Measures to Health-State Utility Values in

Individuals with Migraine. Value in Health 2012;15(3):485-94.

2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburgh AM, Elovic EP. Relationship Between Disability Due to

Upper-Limb Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden, PM&R 2012;4(1):4-10.

Manager, Global Health Economics, Oncology

Amgen, Thousand Oaks, CA

MANUSCRIPTS FROM FELLOWSHIP1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-

Severe Psoriasis: A Bayesian Network Meta-Analysis. Arch Dermatol. 2012 Dec;148(12):1403-10

2. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients’ experience and outcomes after laparoscopic

adjustable gastric banding in Washington State. Surg Obes Relat Dis. 2013 Sep-Oct;9(5):701-5

3. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric

banding: a nonlinear approach. Value in Health. 2013 Jul;16(5):823-9

Consultant, Health Economics and Outcomes Research

Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-

related health resource utilization in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry.

2013 Dec;84(12):1309-17

2. Messali A, Sanderson JC, Blumenfeld AM. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States:

A Web-Based Survey. Headache. 2016 Feb;56(2):306-22

JONATHAN H. WATANABE

PharmD, MS, PhD2007-2009

ZSOLT HEPPPharmD, MS

2012-2014

JOANNA SANDERSON

PharmD, MS2011-2013

VINCENT W. LIN

PharmD, MS2010-2012

PATRICK GILLARD

PharmD, MS2009-2010

KATHARINE S. GRIES

PharmD, MS, PHD2008-2010

10

NYSE:AGN | www.Allergan.com

© 2016 Allergan. ® Marks owned by Allergan. All rights reserved

APPLICATION INFORMATION Interested students must apply to both the University of Washington Graduate School, as well as the Pharmaceutical

Outcomes Research & Policy Program. The online application process can be found at:

http://sop.washington.edu/department-of-pharmacy/pharmaceutical-outcomes-research-policy-program-

porpp/fellowship-opportunities/

CONTACT INFORMATIONIf you have any questions, please contact:

UNIVERSITY OF WASHINGTON

Penny Evans

Graduate Program Advisor

Box 357630

University of Washington

Seattle, WA 98195-7630


Phone: (206) 616-1383

Fax: (206) 543-3835

DEADLINE The application deadline is

December 15, 2016

and the start date of the

Fellowship is July 1, 2017

ALLERGAN PLC

Patrick Gillard, PharmD, MS

Director, GHEOR

2525 Dupont Drive

Irvine, CA 92612


Phone: (714) 246-2354

Applicants for this fellowship must have a degree in pharmacy or health-related

discipline and have some research experience (preference will be given to those with

a high academic standing). Excellent written and verbal communication skills are also

essential. Applicants will be required to submit their curriculum vitae, a letter

describing their career goals, and three letters of recommendation.

Selection of fellows will be made by a steering committee

composed of the University of Washington faculty

members and representatives from Allergan.

APPLICATION ELIGIBILITY

Documents

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH - School of Pharmacy · 2020-02-20 · School of Pharmacy, ... technologies, and (3) translate and disseminate the results of research